OCGN

Ocugen, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.87

Price (1 Year)

$2.48 $0.7

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %24.8 / %30
Non-compliant assets / Total market cap %17.4 / %30
Non-compliant revenue / Total income %76.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Website

Analysis (Turkish): OCGN Hissesi Caiz mi, Helal mi? Ocugen, Inc. Katılım Analizi